Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Development of beraprost for intermittent claudication expected to be dropped

Oct. 17, 2001

GlycoDesign and Leo move new antithrombotics into clinical trials

Oct. 15, 2001

Phase II trial of Argatroban plus gpIIb/IIIa antagonists initiated in patients undergoing PCI

Oct. 10, 2001

Avigen's Coagulin-B gene therapy for hemophilia B trial on clinical hold

Oct. 10, 2001

3-Dimensional Pharmaceuticals to receive milestone payment for thrombin inhibitor program

Oct. 10, 2001

Schering AG acquires rights to Refludan from Aventis

Oct. 9, 2001

Fujisawa reveals new antiplatelet agents

Oct. 8, 2001

NIH supports development of inhaled gene therapy for hemophilia B

Oct. 4, 2001

ProQuest receives grant to study oral formulations of peptides and peptidomimetics

Oct. 2, 2001

GenStar's hemophilia A gene therapy trial resumes after previous delay

Sep. 28, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...